A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis

Journal of Neuroimmunology

Volumn 211, Issue 1-2, 2009, Pages 124-130

  Kaiser, Claudia C ^a   Shukla, Dinesh K ^a   Stebbins, Glenn T ^b   Skias, Demetrios D ^a   Jeffery, Douglas R ^c   Stefoski, Dusan ^b   Katsamakis, George ^b   Feinstein, Douglas L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Atrophy; EDSS; Imaging; MRI; Multiple sclerosis; PPAR

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA1A INTERFERON; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; PIOGLITAZONE; PLACEBO;

ABNORMAL LABORATORY RESULT; ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; BRAIN ATROPHY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAY MATTER; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMAGE ANALYSIS; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; BRAIN; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPROTECTIVE AGENTS; PILOT PROJECTS; THIAZOLIDINEDIONES;

EID: 67349169962     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.04.011     Document Type: Article

References (58)

1. Ashburner J., and Friston K.J. Voxel-based morphometry-the methods. NeuroImage 11 (2000) 805-821
2. Bernardo A., and Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr. Pharm. Des. 12 (2006) 93-109
3. Bernardo A., and Minghetti L. Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPAR Res. 2008 (2008) 864,140
4. Boden G., and Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin. Investig. Drugs 15 (2006) 243-250
5. Bright J.J., Walline C.C., Kanakasabai S., and Chakraborty S. Targeting PPAR as a therapy to treat multiple sclerosis. Expert Opin. Ther. Targets 12 (2008) 1565-1575
6. Chang F., Jaber L.A., Berlie H.D., and O'Connell M.B. Evolution of peroxisome proliferator-activated receptor agonists. Ann. Pharmacother. 41 (2007) 973-983
7. Clark R.B. The role of PPARs in inflammation and immunity. J. Leukoc. Biol. 71 (2002) 388-400
8. Colca J.R., McDonald W.G., Waldon D.J., Leone J.W., Lull J.M., Bannow C.A., Lund E.T., and Mathews W.R. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol., Endocrinol Metabol. 286 (2004) E252-E260
9. Cuadra M.B., Cammoun L., Butz T., Cuisenaire O., and Thiran J.P. Comparison and validation of tissue modelization and statistical classification methods in T1-weighted MR brain images. IEEE Trans. Med. Imag. 24 (2005) 1548-1565
10. Dello Russo C., Gavrilyuk V., Weinberg G., Almeida A., Bolanos J.P., Palmer J., Pelligrino D., Galea E., and Feinstein D.L. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J. Biol. Chem. 278 (2003) 5828-5836
11. Diab A., Deng C., Smith J.D., Hussain R.Z., Phanavanh B., Lovett-Racke A.E., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168 (2002) 2508-2515
12. Drew P.D., Xu J., and Racke M.K. PPAR-gamma: therapeutic potential for multiple sclerosis. PPAR Res. 2008 (2008) 627,463
13. Drew P.D., Xu J., Storer P.D., Chavis J.A., and Racke M.K. Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem. Int. 49 (2006) 183-189
14. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., Gudz T., Macklin W.B., Lewis D.A., Fox R.J., et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 59 (2006) 478-489
15. Duvanel C.B., Honegger P., Pershadsingh H., Feinstein D., and Matthieu J.M. Inhibition of glial cell proinflammatory activities by peroxisome proliferator-activated receptor gamma agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro. J. Neurosci. Res. 71 (2003) 246-255
16. Feinstein D.L. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol. Ther. 5 (2003) 67-73
17. Feinstein D.L., Galea E., Gavrilyuk V., Brosnan C.F., Whitacre C.C., Dumitrescu-Ozimek L., Landreth G.E., Pershadsingh H.A., Weinberg G., and Heneka M.T. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51 (2002) 694-702
18. Fuenzalida K., Quintanilla R., Ramos P., Piderit D., Fuentealba R.A., Martinez G., Inestrosa N.C., and Bronfman M. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J. Biol. Chem. 282 (2007) 37,006-37,015
19. Geurts J., and Barkof F. Grey matter pathology in multiple sclerosis. Lancet 7 (2008) 841-851
20. Good C.D., Johnsrude I.S., Ashburner J., Henson R.N., Friston K.J., and Frackowiak R.S. A voxel-based morphometric study of ageing in 465 normal adult human brains. NeuroImage 14 (2001) 21-36
21. Horakova D., Cox J.L., Havrdova E., Hussein S., Dolezal O., Cookfair D., Dwyer M.G., Seidl Z., Bergsland N., Vaneckova M., et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years. A case control. study. J. Neurol. Neurosurg. Psychiatry 79 (2007) 407-414
22. Isley W.L. Hepatotoxicity of thiazolidinediones. Expert Opin. Drug Safety 2 (2003) 581-586
23. Klotz L., Diehl L., Dani I., Neumann H., von O.N., Dolf A., Endl E., Klockgether T., Engelhardt B., and Knolle P. Brain endothelial PPARgamma controls inflammation-induced CD4(+) T cell adhesion and transmigration in vitro. J. Neuroimmunol. 190 (2007) 34-43
24. Klotz L., Schmidt S., Heun R., Klockgether T., and Kolsch H. Association of the PPARgamma gene polymorphism Pro12Ala with delayed onset of multiple sclerosis. Neurosci. Lett. 449 (2009) 81-83
25. Lebovitz H.E. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab. Res. Rev. 18 Suppl. 2 (2002) S23-S29
26. Luders E., Gaser C., Jancke L., and Schlaug G. A voxel-based approach to gray matter asymmetries. NeuroImage 22 (2004) 656-664
27. Luna-Medina R., Cortes-Canteli M., Alonso M., Santos A., Martinez A., and Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J. Biol. Chem. 280 (2005) 21,453-21,462
28. Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M., and Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47 (1997) 29-35
29. Mestre L., Docagne F., Correa F., Loria F., Hernangomez M., Borrell J., and Guaza C. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol. Cell. Neurosci. 40 2 (2008) 258-266
30. Miller D.H., Thompson A.J., and Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J. Neurol. 250 (2003) 1407-1419
31. Miller D.H., MacManus D.H., Miszkiel K.A., Giovannoni G., and Young C. An exploratory study of rosiglitazone maleate in relapsing-remitting multiple sclerosis. Multiple Sclerosis 7 (2005) S164
32. Natarajan C., and Bright J.J. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun. 3 (2002) 59-70
33. Natarajan C., Muthian G., Barak Y., Evans R.M., and Bright J.J. Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J. Immunol. 171 (2003) 5743-5750
34. Niino M. Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis. Mini Rev. Med. Chem. 7 (2007) 1129-1135
35. Niino M., Iwabuchi K., Kikuchi S., Ato M., Morohashi T., Ogata A., Tashiro K., and Onoe K. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J. Neuroimmunol. 116 (2001) 40-48
36. Ou Z., Zhao X., Labiche L.A., Strong R., Grotta J.C., Herrmann O., and Aronowski J. Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARgamma) and 15d-prostaglandin J2-mediated protection of brain after experimental cerebral ischemia in rat. Brain Res. 1096 (2006) 196-203
37. Paddock M.L., Wiley S.E., Axelrod H.L., Cohen A.E., Roy M., Abresch E.C., Capraro D., Murphy A.N., Nechushtai R., Dixon J.E., et al. MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 14,342-14,347
38. Park S.W., Yi J.H., Miranpuri G., Satriotomo I., Bowen K., Resnick D.K., and Vemuganti R. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J. Pharmacol. Exp. Ther. 320 (2007) 1002-1012
39. Pellerin L., Bouzier-Sore A.K., Aubert A., Serres S., Merle M., Costalat R., and Magistretti P.J. Activity-dependent regulation of energy metabolism by astrocytes: an update. Glia 55 (2007) 1251-1262
40. Pershadsingh H.A., Heneka M.T., Saini R., Amin N.M., Broeske D.J., and Feinstein D.L. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J. Neuroinflamm. 1 (2004) 3
41. Peterson J., Bo L., Mork S., Chang A., and Trapp B. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50 (2001) 389-400
42. Racke M.K., Gocke A.R., Muir M., Diab A., Drew P.D., and Lovett-Racke A.E. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J. Nutr. 136 (2006) 700-703
43. Raikwar H.P., Muthian G., Rajasingh J., Johnson C., and Bright J.J. PPARgamma antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis. J. Neuroimmunol. 167 (2005) 99-107
44. Ramirez S.H., Heilman D., Morsey B., Potula R., Haorah J., and Persidsky Y. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes. J. Immunol. 180 (2008) 1854-1865
45. Romera C., Hurtado O., Mallolas J., Pereira M.P., Morales J.R., Romera A., Serena J., Vivancos J., Nombela F., Lorenzo P., et al. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. J. Cereb. Blood Flow Metab. 27 (2007) 1327-1338
46. Sanfilipo M.P., Benedict R.H., Sharma J., Weinstock-Guttman B., and Bakshi R. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white. matter. with. misclassification. correction. NeuroImage. 26 (2005) 1068-1077
47. Schmidt S., Moric E., Schmidt M., Sastre M., Feinstein D.L., and Heneka M.T. Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J. Leukoc. Biol. 75 (2004) 478-485
48. Sim F.J., Lang J.K., Ali T.A., Roy N.S., Vates G.E., Pilcher W.H., and Goldman S.A. Statin treatment of adult human glial progenitors induces PPAR gamma-mediated oligodendrocytic differentiation. Glia 56 (2008) 954-962
49. Stadelmann C., Albert M., Wegner C., and Brück W. Cortical pathology in multiple sclerosis. Curr. Opin. Neurol. 21 (2008) 229-234
50. Storer P.D., Xu J., Chavis J., and Drew P.D. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J. Neuroimmunol. 161 (2005) 113-122
51. Tiberio M., Chard D.T., Altmann D.R., Davies G., Griffin C.M., Rashid W., Sastre-Garriga J., Thompson A.J., and Miller D.H. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 64 (2005) 1001-1007
52. Tureyen K., Kapadia R., Bowen K.K., Satriotomo I., Liang J., Feinstein D.L., and Vemuganti R. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J. Neurochem. 101 (2007) 41-56
53. Uryu S., Harada J., Hisamoto M., and Oda T. Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res. 924 (2002) 229-236
54. Valsasina P., Benedetti B., Rovaris M., Sormani M.P., Comi G., and Filippi M. Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology 65 (2005) 1126-1128
55. Werner P., Pitt D., and Raine C.S. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann. Neurol. 50 (2001) 169-180
56. Xu J., and Drew P.D. Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J. Immunol. 178 (2007) 1904-1913
57. Zhao X., Ou Z., Grotta J.C., Waxham N., and Aronowski J. Peroxisome-proliferator-activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. Brain Res. 1073-1074 (2006) 460-469
58. Zivadinov R., Locatelli L., Cookfair D., Srinivasaraghavan B., Bertolotto A., Ukmar M., Bratina A., Maggiore C., Bosco A., Grop A., et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult. Scler. 13 (2007) 490-501